{"id":672429,"date":"2023-10-16T18:36:01","date_gmt":"2023-10-16T18:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=672429"},"modified":"2023-10-16T18:36:01","modified_gmt":"2023-10-16T18:36:01","slug":"osteomyelitis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-adaptive-phage-therapeutics-durata-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/osteomyelitis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-adaptive-phage-therapeutics-durata-therapeutics_672429.html","title":{"rendered":"Osteomyelitis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies &#8211; Adaptive Phage Therapeutics, Durata Therapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\" Osteomyelitis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - Adaptive Phage Therapeutics, Durata Therapeutics \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\" Osteomyelitis Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - Adaptive Phage Therapeutics, Durata Therapeutics \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Osteomyelitis\u2014Market Insights, Epidemiology, and Market Forecast\u20142032\u2019 report delivers an in-depth understanding of osteomyelitis, historical and forecasted epidemiology, as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Osteomyelitis&mdash;Market Insights, Epidemiology, and Market Forecast&mdash;2032<\/a><\/strong>&rsquo; report delivers an in-depth understanding of osteomyelitis, historical and forecasted epidemiology, as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Highlights of Osteomyelitis&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Companies working in the Osteomyelitis market include Durata Therapeutics IncAllergan plc, Basilea Pharmaceutica, Adaptive Phage Therapeutics, and many others.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Therapies included in the Osteomyelitis market are Dalbavancin, Comparator, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteomyelitis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Osteomyelitis is an acute infection of the bone that can occur from direct or indirect invasion by a pathogen. Direct invasion is also referred to as exogenous or acute contagious osteomyelitis and can occur at any time if there is an open wound in the body. Indirect invasion is also referred to as endogenous or acute hematogenous osteomyelitis and usually occurs from the spread of systemic infection. Both of these types can potentially progress to subacute and chronic osteomyelitis. Acute osteomyelitis typically refers to an infection of less than 1 month duration, whereas chronic osteomyelitis refers to an infection that lasts longer than 4 weeks.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Optimal treatment of skeletal infections requires collaborative efforts of pediatricians, orthopedic surgeons, and interventional radiologists. Antibiotics can make up an effective treatment regimen but may include the surgical removal of dead bone in chronic osteomyelitis. Painkillers are given to ease the pain. In neglected cases with flexion contractures, prolonged physical therapy is required.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A few major unmet needs in the market include a lack of novel and effective strategies for antibiotic therapy, challenges in diagnosis, difficulty in establishing microbial etiology, antimicrobial resistance, and lack of clarity in the role of surgical debridement in treating chronic osteomyelitis.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/d568f1e95464f9a118643d96ffdc6840.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Osteomyelitis Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Osteomyelitis&nbsp; Epidemiology Segmented by<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Osteomyelitis prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Osteomyelitis incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Osteomyelitis treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Osteomyelitis diagnosed cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteomyelitis Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Osteomyelitis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Osteomyelitis market trends by analyzing the impact of current Osteomyelitis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of the Osteomyelitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Osteomyelitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the Osteomyelitis Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Durata Therapeutics IncAllergan plc<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Basilea Pharmaceutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Adaptive Phage Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteomyelitis Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dalbavancin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Comparator<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Key Companies and Emerging Therapies in the Osteomyelitis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Osteomyelitis&nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Osteomyelitis&nbsp; &nbsp; &nbsp; &#8211;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Osteomyelitis&nbsp; Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Osteomyelitis&nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteomyelitis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Osteomyelitis Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=osteomyelitis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-adaptive-phage-therapeutics-durata-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=osteomyelitis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-adaptive-phage-therapeutics-durata-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Osteomyelitis\u2014Market Insights, Epidemiology, and Market Forecast\u20142032\u2019 report delivers an in-depth understanding of osteomyelitis, historical and forecasted epidemiology, as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/osteomyelitis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-study-period-2019-2032key-companies-adaptive-phage-therapeutics-durata-therapeutics_672429.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-672429","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/672429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=672429"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/672429\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=672429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=672429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=672429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}